1. CKD patients showed upregulation of SMAD3 and NLRP3. 2. Plasma and urine levels of TMAO are significantly high in CKD patients with elevated serum TGF-β1 and IL-1β levels. TMAO can be used as a marker for CKD progression. This evidence concerns the gene IL1B and chronic kidney disease.